ERLANGEN, Germany--(BUSINESS WIRE)--Siemens Healthineers and Healthy.io have announced today a global OEM alliance to help patients improve their compliance with Chronic Kidney Disease (CKD) monitoring. It is estimated that between 8-10 percent of the adult population globally have some form of kidney damage.1 Undetected CKD can lead to kidney failure, and also increase a patient’s risk of premature death from associated cardiovascular diseases. For these reasons, regular monitoring is important for improved patient outcomes.

MALVERN, Pa.--(BUSINESS WIRE)--Siemens Healthineers has announced the first global installation of its newest ultrasound system, the Acuson Sequoia, at Baptist Health South Florida. With ten facilities and five “centers of excellence” in the South Florida region, Baptist Health South Florida purchased numerous Acuson Sequoia systems in order to enhance its imaging capabilities within the scope of gastroenterology, primary care, and bariatric specialties.

Clinical laboratories are challenged to meet greater testing demands, improve efficiency, and deliver reliable, high-quality results, while facing an increasing shortage of skilled employees1 and growing budget constraints. Recognizing that technology can play a critical role in addressing each of these challenges, Siemens Healthineers brought to market the Atellica® Solution2 immunoassay and clinical chemistry analyzers for in vitro diagnostic testing.

Siemens Healthineers announced today it is helping to shorten the time doctors can diagnose a life-threatening heart attack with the introduction of two assays that offer unparalleled precision. U.S. Food and Drug Administration cleared High-Sensitivity Troponin I assays (TnIH)1 for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers from Siemens Healthineers to aid in the early diagnosis of myocardial infarctions—commonly known as heart attacks.